ArticleScientific reports2024
Label-free visualization and quantification of the drug-type-dependent response of tumor spheroids by dynamic optical coherence tomography.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Intrinsically co-registered extended-depth-of-focus OCM and two-photon microscopy for label-free volumetric analysis of 3D cell models.Biomedical optics express · 2026Article
- Label-free 4D holotomography with depth-adaptive segmentation for quantitative analysis of lipid droplet dynamics in hepatic organoids.Biophotonics discovery · 2026Article
- Dynamic full-field swept-source optical coherence tomography for high-resolution, long-depth, and intratissue-activity imaging.Biomedical optics express · 2026Article
- Dynamic optical coherence microscope integrated with cell-cultivation chamber enabled longitudinal and early-stage assessment of tumor spheroid-drug interaction.Scientific reports · 2026Article
- Article
- Optical coherence photoacoustic microscopy for 3D cancer model imaging with AI-assisted organoid analysis.Light, science & applications · 2026Article
- Longitudinal investigation of prostate tumor spheroid proliferation with dynamic line-field optical coherence tomography.Biomedical optics express · 2026Article
- Thermoresponsive nanoparticles for targeted and controlled delivery of doxorubicin in triple negative breast cancer: a 2D and 3D in vitro evaluation.Drug delivery and translational research · 2026Article
- Evaluating the Efficacy of Mebendazole Repurposing for Ovarian Cancer Therapy Using Optical Coherence Tomography.Journal of biophotonics · 2026Article
- Dynamic optical coherence tomography algorithm for label-free assessment of swiftness and occupancy of intratissue moving scatterers.Biomedical optics express · 2026Article
- Dynamic contrast in dual-beam optical coherence tomography imaging of human skin.Biomedical optics express · 2025Article
- Review of dynamic optical coherence tomography for intracellular motility: signals, metrics, and their applications [Invited].Biomedical optics express · 2025Review
- Quantitative and longitudinal monitoring of cancer cell invasion in a three-dimensional in vitro model of oral cancer using optical coherence tomography.Scientific reports · 2025Article
- A knowledge-driven deep learning framework for organoid morphological segmentation and characterization.BMC biology · 2025Article
- Label-Free Machine Learning Prediction of Chemotherapy on Tumor Spheroids Using a Microfluidics Droplet Platform.Small science · 2025Article
- A modular and reconfigurable microfluidic device for culturing spheroids under continuous perfusion.APL bioengineering · 2025Article
- Experimental and numerical investigation of wavelength and resolution dependency of dynamic optical coherence tomography signals.Biomedical optics express · 2025Article
- Bridging the gap: the role of 3D cell cultures in mimicking tumor microenvironment for enhanced drug testing accuracy.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
We demonstrate label-free dynamic optical coherence tomography (D-OCT)-based visualization and quantitative assessment of patterns of tumor spheroid response to three anti-cancer drugs. The study involved treating human breast adenocarcinoma (MCF-7 cell-line) with paclitaxel (PTX), tamoxifen citrate (TAM), and doxorubicin (DOX) at concentrations of 0 (control), 0.1, 1, and 10 µM for 1, 3, and 6 days. In addition, fluorescence microscopy imaging was performed for reference. The D-OCT imaging was performed using a custom-built OCT device. Two algorithms, namely logarithmic intensity variance (LIV) and late OCT correlation decay speed (OCDS[Formula: see text]) were used to visualize the tissue dynamics. The spheroids treated with 0.1 and 1 µM TAM appeared similar to the control spheroid, whereas those treated with 10 µM TAM had significant structural corruption and decreasing LIV and OCDS[Formula: see text] over treatment time. The spheroids treated with PTX had decreasing volumes and decrease of LIV and OCDS[Formula: see text] signals over time at most PTX concentrations. The spheroids treated with DOX had decreasing and increasing volumes over time at DOX concentrations of 1 and 10 µM, respectively. Meanwhile, the LIV and OCDS[Formula: see text] signals decreased over treatment time at all DOX concentrations. The D-OCT, particularly OCDS[Formula: see text], patterns were consistent with the fluorescence microscopic patterns. The diversity in the structural and D-OCT results among the drug types and among the concentrations are explained by the mechanisms of the drugs. The presented results suggest that D-OCT is useful for evaluating the difference in the tumor spheroid response to different drugs and it can be a useful tool for anti-cancer drug testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.